Latest news with #AstraZenecaPharmaIndia
&w=3840&q=100)
Business Standard
18-07-2025
- Business
- Business Standard
Here's why AstraZeneca Pharma share price is down over 2% today
AstraZeneca Pharma share price: Shares of pharma major AstraZeneca Pharma India dropped 2.5 per cent to ₹9,165 per share during intraday deals on Friday and continued to trade lower. At around 2:20 PM, they were trading at approximately ₹9,165 per share, down 2.10 per cent from their previous close of ₹9,394 on the NSE. A combined nearly 0.17 lakh equity shares of AstraZeneca Pharma, estimated to be worth around ₹16 crore, changed hands on the BSE and NSE. Here's why AstraZeneca Pharma's share price declined today The decline in the company's share price came as the company's shares traded ex-date following its announcement of dividend rewards of ₹32 per share for the financial year 2024–25 (FY25). Notably, the ex-dividend date marks the day a stock begins trading without the value of its declared dividend. To be eligible for the dividend, investors must own the stock before the ex-dividend date. AstraZeneca Pharma dividend record date AstraZeneca Pharma dividend history The company has a strong history of awarding dividends. According to NSE data, it paid ₹8 per share in 2022, ₹16 per share in 2023, and ₹24 per share in 2024 to its shareholders. AstraZeneca Pharma dividend yield At the current market price, AstraZeneca Pharma has a dividend yield of 0.35 per cent. About AstraZeneca Pharma AstraZeneca Pharma, a subsidiary of AstraZeneca Plc (UK), is engaged in the manufacture, distribution, and marketing of pharmaceutical products, and coordinates clinical trial services with its overseas group company. The company operates across major therapeutic areas including oncology, alimentary & metabolism, cardiovascular, renal diabetes, respiratory, infections, neuroscience, and inflammation. As of July 18, the pharma major boasts a market capitalisation of ₹22,912.50 crore on the NSE. AstraZeneca Pharma share price history AstraZeneca Pharma's share price has appreciated 42 per cent year-to-date, compared to a 5 per cent gain in the benchmark Nifty50 during the same period. The shares scaled a 52-week high of ₹10,691 on June 13, 2025, and hit a 52-week low of ₹6,220 on November 21, 2024, on the NSE.
Business Standard
02-07-2025
- Business
- Business Standard
AstraZeneca Pharma gets CDSCO approval to import Durvalumab Solution
AstraZeneca Pharma India said that it has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of Durvalumab Solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi). Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR). AstraZeneca Pharma is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. The companys consolidated net profit jumped 57.7% to Rs 62.27 crore on 25.4% increase in net sales to Rs 480.48 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.13% to Rs 8,886.50 on the BSE.
Time of India
02-07-2025
- Business
- Time of India
AstraZeneca Pharma India shares rise over 2% after CDSCO clears Imfinzi for new cancer use
Shares of AstraZeneca Pharma India rose over 2% to Rs 9100 on BSE in Wednesday's trade after the company received regulatory approval for a new use of its cancer therapy Imfinzi. On Tuesday, AstraZeneca Pharma India announced that it has received clearance from the Central Drugs Standard Control Organisation (CDSCO) to import durvalumab solution for infusion (brand name: Imfinzi) in 120 mg/2.4 ml and 500 mg/10 ml strengths for an additional indication. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trekking pants for mountain sports and adventure travel Trek Kit India Shop Now The CDSCO approval allows Imfinzi, in combination with carboplatin and paclitaxel, to be used as a first-line treatment for adults with primary, advanced, or recurrent endometrial cancer who are candidates for systemic therapy. The treatment will be followed by maintenance therapy using durvalumab and olaparib for patients with mismatch repair proficient (pMMR) endometrial cancer. 'This regulatory clearance enables AstraZeneca to market the approved formulation of Imfinzi in India for the specified indication, subject to other applicable statutory approvals,' the company said in a statement. Impressive fourth-quarter earnings Live Events The regulatory development comes on the heels of a strong earnings report by AstraZeneca Pharma India. The company posted a 47.7% year-on-year jump in net profit to Rs 58.2 crore for the quarter ended March 2025, up from Rs 39.4 crore a year earlier. Revenue for the quarter rose 25.4% to Rs 480.4 crore compared with Rs 383.2 crore in the same period last year, supported by "continued demand across its key therapy areas and improved market penetration". Earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 74.7% to Rs 86.3 crore, compared to Rs 49.4 crore a year ago. The EBITDA margin improved sharply to 17.96%, up from 12.89%. The management attributed the robust financial performance to "continued investment in innovation and its portfolio of newer-generation therapies in the oncology, cardiovascular, and respiratory segments". Stock performance and technical setup On Tuesday, shares of AstraZeneca Pharma India closed at Rs 8,890 on the BSE, up by Rs 18.30 or 0.21%. The stock has gained 39.2% in the past year and 23.7% over the last six months. In the last three months, the shares are up nearly 5%, and have risen 11.6% in the past one month. From a technical perspective, the stock is currently trading below its 10-day, 20-day, and 30-day simple moving averages (SMAs), but remains above its 5-day, 50-day, 100-day, 150-day, and 200-day SMAs. The Relative Strength Index (RSI) stands at 45.7, suggesting neutral momentum. The Moving Average Convergence Divergence (MACD) is at 1.3, above the center line but below the signal line, indicating a potential pause in recent momentum.
Business Standard
10-06-2025
- Business
- Business Standard
AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge
AstraZeneca Pharma India declined 1.57% to Rs 9,878 after the company said its managing director (MD), Sanjeev Kumar Panchal has resigned from his position with effect from the close of business on 30 June 2025. Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaithersburg, Maryland, US. The board acknowledged his resignation and placed on record its appreciation for his contributions during his tenure. Following the recommendation of the nomination and remuneration committee, the board has approved the appointment of Praveen Rao Akkinepally as the new MD. He will take charge from 1 July 2025, for a term of three years. Akkinepally is a senior commercial leader with over two decades of experience across the US, global markets, and India, particularly in oncology and biopharmaceuticals. He has led several brand launches and driven global commercial strategies at AstraZeneca. His previous role as oncology business unit head for India saw significant growth in the companys market presence and a series of successful oncology product launches. Beyond his corporate achievements, he has contributed to healthcare policy through his work with the Federation of Indian Chambers of Commerce and Industrys cancer round tables. Akkinepally holds an MBA from the University of Michigans Ross School of Business and a masters in public health from Johns Hopkins University. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024.
&w=3840&q=100)
Business Standard
02-06-2025
- Business
- Business Standard
AstraZeneca Pharma shares surge 12% after Q4 results; profit jumps 48%
Shares of AstraZeneca Pharma India rallied nearly 12 per cent on Monday after its net profit for the fourth quarter of the previous financial year (Q4 FY25) jumped 48 per cent to ₹58.25 crore year-on-year (Y-o-Y). The pharma major's stock rose as much as 11.87 per cent during the day to ₹8,919 per share, the biggest intraday gain since March 20 this year. The stock pared gains to trade 11.2 per cent higher at ₹8,875 apiece, compared to a 0.54 per cent decline in Nifty50 as of 10:54 AM. Shares of the company extended gains to their third day while they have fallen 21 per cent this year, compared to a 4.1 per cent advance in the benchmark Nifty50. AstraZeneca Pharma has a total market capitalisation of ₹22,195.5 crore, according to BSE data. Track LIVE Stock Market Updates Here AstraZeneca Pharma Q4 results The pharma major reported a 48 per cent rise in consolidated net profit for Q4 FY24 to ₹58.25 crore. Total revenue from operations stood at ₹480.48 crore, up 25.3 per cent Y-o-Y. The company also recorded significant growth across therapeutic areas, achieving a 32 per cent increase in full-year revenue compared to the previous year. In its oncology business, the pharma major reported revenue of ₹315.85 crore in Q4FY25, a rise of 31.62 per cent. Additionally, revenue from biopharmaceuticals (cardiovascular, renal and metabolism; respiratory and immunology; and vaccines and immune therapies) rose 1.9 per cent to ₹122.74 crore. The rare disease segment grew to Rs 2 crore in Q4FY25, up from Rs 0.17 crore in Q4FY24. AstraZeneca Pharma management commentary 'FY2024–25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent," said Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma. "This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet.' About AstraZeneca Pharma AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation. The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid–19 vaccine
